One structural class, one treatment? Firmonertinib in PACC-mutant NSCLC.

Firmonertinib shows promising systemic and intracranial efficacy in preclinical models of PACC-mutant NSCLC, supporting its further clinical development.

• Why it matters: Limited treatment options exist for EGFR PACC-mutant NSCLC, making new targeted therapies crucial for improving patient outcomes in this challenging mutation class.
• What they did: Le et al. conducted preclinical studies evaluating firmonertinib, a broad-spectrum CNS-penetrant tyrosine kinase inhibitor, demonstrating its potential effectiveness against PACC-mutant NSCLC.
• The result: The findings suggest that firmonertinib may be a valuable treatment option for PACC-mutant NSCLC, particularly due to its systemic and intracranial activity, warranting further clinical investigation.